title: [Epoch making development of new drugs for prostate cancer].
abstract: Prostate cancer responds well to androgen depletion therapy(ADT). However, when ADT was initiated on advanced prostate cancer, many become Castration-Resistant Prostate Cancer(CRPC)within a few years. Thus, development of new agents against CRPC is warranted. At the 2012 ASCO Meeting, results from two global randomized trials were given a warm reception. One trial involved abiraterone acetate and the other MDV3100.
authors.affiliation: Dept. of Strategic Investigation on Comprehensive Cancer Network, University of Tokyo, Tokyo, Japan.
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Akaza
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D015195:Drug Design; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents